The need for better legislation for generic drug manufacturers

0 / 5 (0 votos)

The Lancet Haematology

Published: July 2017


Last month, Aspen Pharmaceuticals were in the spotlight for price hikes on five drugs that had been acquired from GlaxoSmithKline in 2009. The drugs—which include chlorambucil and mercaptopurine for the treatment of chronic lymphocytic leukaemia, and tioguanine, melphalan, and bulsafan for the treatment of other haematological malignancies—were about to be released from their patent and were traded from GlaxoSmithKline to Aspen, a South Africa-based generics company, in a deal that included a 16% market share of the company. By 2016, the price of melphalan in the UK had risen to…

Seguir leyendo